BNP Paribas Financial Markets
CLYM

BNP Paribas Financial Markets’s Climb Bio CLYM Stock Holding History

BNP Paribas Financial Markets’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Buy
29,128
+28,615
+5,578% +$165K ﹤0.01% 4052
2025
Q4 		$2.05K Sell
513
-1,341
-72% -$3.22K ﹤0.01% 5346
2025
Q3 		$3.73K Sell
1,854
-5,815
-76% -$10.8K ﹤0.01% 5122
2025
Q2 		$9.51K Buy
7,669
+1,906
+33% +$2.37K ﹤0.01% 4852
2025
Q1 		$7.03K Sell
5,763
-38,130
-87% -$61.8K ﹤0.01% 4794
2024
Q4 		$79K Buy
+43,893
New +$159K ﹤0.01% 4247
2022
Q4 		– Sell
-158
Closed -$510 – 4707
2022
Q3 		$510 Buy
+158
New +$504 ﹤0.01% 4515

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

BNP Paribas Financial Markets's CLYM Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Climb Bio (CLYM) stake by 5,578% in Q1 2026, buying an estimated $165K and bringing the position to 29,128 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #4052.

BNP Paribas Financial Markets first reported a position in CLYM in Q3 2022 and has held it in 7 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • BNP Paribas Financial Markets held 29,128 shares of Climb Bio worth $200K as of Q1 2026.
  • BNP Paribas Financial Markets bought 28,615 Climb Bio shares in Q1 2026, an estimated $165K.
  • Climb Bio made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4052 holding.
  • BNP Paribas Financial Markets first reported a position in Climb Bio in Q3 2022 and has held it in 7 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.